echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > STTT: The domestic multi-center study ORIENT-4 confirmed that the PD-1 inhibitor sintilimab (sintilimab) is effective and tolerable in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL) good

    STTT: The domestic multi-center study ORIENT-4 confirmed that the PD-1 inhibitor sintilimab (sintilimab) is effective and tolerable in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL) good

    • Last Update: 2022-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a highly aggressive non-Hodgkin lymphoma (NHL) subtype with a high incidence in Asia and Latin America


    Lymphoma infection immunity

    ORIENT-4 is a multi-center, single-arm, phase 2 clinical trial (NCT03228836)


    From August 31, 2017 to February 7, 2018, 34 patients were screened , and 28 patients were finally enrolled


    Screening for stem cells

    As of February 28, 2020, the median follow-up time was 30.



    The median follow-up was 30.



    Twenty-seven patients (96.


    Diabetes Digestion


    In summary, the ORIENT-4 study shows that the PD-1 inhibitor sintilimab (sintilimab) is effective and well tolerated in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL)


    Original source:

    Tao R, Fan L, Song Y, Hu Y, Zhang W, Wang Y, Xu W, Li J.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.